Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Riaz ul-Haq +19 more
core
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra +5 more
wiley +1 more source
A dual origin for Bcr-Abl gene translocation/fusion as dynamics of synergism of the hematopoietic stem cell and hemangioblast in chronic myeloid leukemia [PDF]
Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core +1 more source
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James +9 more
doaj +1 more source
Abstract Background Newly positive hepatitis B virus (HBV) serologic results after allogeneic hematopoietic cell transplantation (HCT) may reflect passive antibody transfer from blood‐derived products rather than HBV infection. We investigated the incidence and temporal patterns of hepatitis B surface antibody (anti‐HBs) and antibody to hepatitis B ...
Takaaki Konuma +7 more
wiley +1 more source
Case 37-1994: Juvenile chronic myelogenous leukemia
To the Editor: The case report in the October 13 issue1 describes a newborn boy with juvenile chronic myelogenous leukemia that was diagnosed on the basis of “an open-liver biopsy, which revealed an extensive...
Grabowski E. F. +6 more
core +1 more source
Avaliação de parâmetros laboratoriais e clínicos de pacientes portadores de leucemia mielóide crônica submetidos ao tratamento com mesilato de imatinibe e sua relação com alterações observadas no estroma da medula óssea Correlation between laboratory and clinical parameters of chronic myeloid leukemia patients treated with imatinib mesylate and its relationship with stromal changes observed in bone marrow biopsy [PDF]
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-graduação em FarmáciaA leucemia mieloide cronica (LMC) e uma doenca mieloproliferativa clonal, responsavel por 14% de todos os casos de ...
Caroline R. de Jesus +1 more
core +1 more source
ABSTRACT Cancer survivors have an elevated risk of developing subsequent primary cancers, including colorectal cancer (CRC), and may benefit from tailored screening approaches to reduce incidence and morbidity. A retrospective cohort of adults diagnosed with cancer (excluding CRC) in Alberta, Canada from 2000 to 2021 who survived at least 6 months was ...
Dylan E. O'Sullivan +9 more
wiley +1 more source
Characteristics of patients with chronic myelogenous leukemia.
Ke Ding (309244) +5 more
core +1 more source
Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib [PDF]
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Holyoake, T.L. +9 more
core +1 more source

